Table 1. Baseline data of 39 patients chronically infected with HCV, genotype 1, divided in groups with either SVR or non-SVR following pegylated interferon/ribavirin treatment.
| SVR | Non-SVR | |
| Total | 23 | 16 |
| 1a | 14 (61%) | 12 (75%) |
| 1b | 9 (39%) | 3 (19%) |
| Not determined | 0 (0%) | 1 (6%) |
| Male | 16 (70%) | 11 (69%) |
| Female | 7 (30%) | 5 (31%) |
| Intravenous drug users (IDU) | 6 (26%) | 8 (50%) |
| Non-IDU | 6 (26%) | 5 (31%) |
| Unknown | 11 (48%) | 3 (18%) |
| European | 19 (83%) | 14 (88%) |
| Non-European | 4 (17%) | 2 (12%) |
| BMI >25 | 10 (43%) | 8 (50%) |
| BMI ≤25 | 10 (43%) | 5 (31%) |
| Unknown | 3 (13%) | 3 (19%) |
| Biopsy yes | 16 (70%) | 10 (63%) |
| Biopsy no | 7 (30%) | 6 (37%) |
| Cirrhosis yes* | 3 (19%) | 6 (60%) |
| Cirrhosis no* | 13 (81%) | 4 (40%) |
| Age ≤45 | 8 (34%) | 3 (19%) |
| Age >45 | 15 (65%) | 13 (81%) |
| HCV RNA ≥600.000 | 16 (70%) | 10 (63%) |
| HCV RNA <600.000 | 7 (30%) | 6 (37%) |
| ALT ≥70/100 | 13 (57%) | 8 (50%) |
| ALT <70/100 | 10 (43%) | 8 (50%) |
| Treatment duration ≥48 weeks | 18 (78%) | 6 (37%) |
| Treatment duration <48 weeks | 5 (22%) | 10 (63%) |
The data is shown in absolute numbers and percent of the total in the group. None of the baseline data was significant predictors of pegylated interferon/ribavirin treatment outcome in this cohort.
*
only patients with a biopsy were included. SVR = sustained virologic response, non-SVR = non sustained virologic response.